Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 297

1.

A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.

Lynce F, Wang H, Petricoin EF, Pohlmann PR, Smaglo B, Hwang J, He AR, Subramaniam DS, Deeken J, Marshall J, Pishvaian MJ.

Cancer Chemother Pharmacol. 2019 Nov;84(5):1145-1151. doi: 10.1007/s00280-019-03947-7. Epub 2019 Sep 19.

PMID:
31538230
2.

Antitumor effect of insulin-like growth factor-1 receptor inhibition in head and neck squamous cell carcinoma.

Lehman CE, Khalil AA, Axelrod MJ, Dougherty MI, Schoeff SS, Taniguchi LE, Mendez RE, David AP, McGarey PO Jr.,, Hubbard MA, Donaldson L, Frierson HF Jr.,, Stelow EB, Bekiranov S, Wulfkuhle JD, Petricoin EF, Gioeli DG, Jameson MJ.

Laryngoscope. 2019 Aug 21. doi: 10.1002/lary.28236. [Epub ahead of print]

PMID:
31433065
3.

Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones.

Tew BY, Legendre C, Schroeder MA, Triche T, Gooden GC, Huang Y, Butry L, Ma DJ, Johnson K, Martinez RA, Pierobon M, Petricoin EF, O'Shaughnessy J, Osborne C, Tapia C, Buckley DN, Glen J, Bernstein M, Sarkaria JN, Toms SA, Salhia B.

Neuro Oncol. 2019 Aug 21. pii: noz137. doi: 10.1093/neuonc/noz137. [Epub ahead of print]

PMID:
31433055
4.

Dynamic Regulation of Caveolin-1 Phosphorylation and Caveolae Formation by Mammalian Target of Rapamycin Complex 2 in Bladder Cancer Cells.

Hau AM, Gupta S, Leivo MZ, Nakashima K, Macias J, Zhou W, Hodge A, Wulfkuhle J, Conkright B, Bhuvaneshwar K, Rao S, Madhavan S, Petricoin EF 3rd, Hansel DE.

Am J Pathol. 2019 Sep;189(9):1846-1862. doi: 10.1016/j.ajpath.2019.05.010. Epub 2019 Jun 11.

PMID:
31199921
5.

Development of a multicellular pancreatic tumor microenvironment system using patient-derived tumor cells.

Gioeli D, Snow CJ, Simmers MB, Hoang SA, Figler RA, Allende JA, Roller DG, Parsons JT, Wulfkuhle JD, Petricoin EF, Bauer TW, Wamhoff BR.

Lab Chip. 2019 Mar 27;19(7):1193-1204. doi: 10.1039/c8lc00755a.

PMID:
30839006
6.

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.

Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, Diehl JN, Goode GD, Chaika NV, Wang Y, Zhang GF, Witkiewicz AK, Knudsen ES, Petricoin EF 3rd, Singh PK, Macdonald JM, Tran NL, Lyssiotis CA, Ying H, Kimmelman AC, Cox AD, Der CJ.

Nat Med. 2019 Apr;25(4):628-640. doi: 10.1038/s41591-019-0368-8. Epub 2019 Mar 4.

7.

Network proteomics of human dermal wound healing.

Gao X, Petricoin EF 3rd, Ward KR, Goldberg SR, Duane TM, Bonchev D, Arodz T, Diegelmann RF.

Physiol Meas. 2018 Dec 7;39(12):124002. doi: 10.1088/1361-6579/aaee19.

PMID:
30524050
8.

Phosphoprotein-based drug target activation mapping for precision oncology: a view to the future.

Pierobon M, Petricoin EF 3rd, Wulfkuhle JD.

Expert Rev Proteomics. 2018 Nov;15(11):851-853. doi: 10.1080/14789450.2018.1531709. Epub 2018 Oct 12. No abstract available.

PMID:
30301389
9.

An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease.

Younossi ZM, Karrar A, Pierobon M, Birerdinc A, Stepanova M, Abdelatif D, Younoszai Z, Jeffers T, Felix S, Jeiran K, Hodge A, Zhou W, Monge F, Alaparthi L, Chandhoke V, Goodman ZD, Petricoin EF.

BMC Med. 2018 Sep 12;16(1):170. doi: 10.1186/s12916-018-1136-1.

10.

Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative.

Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, Chung V, Picozzi VJ, Sohal D, Blais EM, Mason K, Lyons EE, Matrisian LM, Brody JR, Madhavan S, Petricoin EF 3rd.

Clin Cancer Res. 2018 Oct 15;24(20):5018-5027. doi: 10.1158/1078-0432.CCR-18-0531. Epub 2018 Jun 28.

11.

Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma.

deCarvalho AC, Kim H, Poisson LM, Winn ME, Mueller C, Cherba D, Koeman J, Seth S, Protopopov A, Felicella M, Zheng S, Multani A, Jiang Y, Zhang J, Nam DH, Petricoin EF, Chin L, Mikkelsen T, Verhaak RGW.

Nat Genet. 2018 May;50(5):708-717. doi: 10.1038/s41588-018-0105-0. Epub 2018 Apr 23.

12.

Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015.

Pollmann SE, Calvert VS, Rao S, Boca SM, Madhavan S, Horak ID, Kjaer A, Petricoin EF, Kragh M, Poulsen TT.

Mol Cancer Ther. 2018 Jun;17(6):1259-1270. doi: 10.1158/1535-7163.MCT-17-0787. Epub 2018 Mar 15.

13.

Correction: Phosphoproteomic analysis reveals Smad protein family activation following Rift Valley fever virus infection.

de la Fuente C, Pinkham C, Dabbagh D, Beitzel B, Garrison A, Palacios G, Hodge KA, Petricoin EF, Schmaljohn C, Campbell CE, Narayanan A, Kehn-Hall K.

PLoS One. 2018 Mar 15;13(3):e0194633. doi: 10.1371/journal.pone.0194633. eCollection 2018.

14.

Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice.

Blohm-Mangone K, Burkett NB, Tahsin S, Myrdal PB, Aodah A, Ho B, Janda J, McComas M, Saboda K, Roe DJ, Dong Z, Bode AM, Petricoin EF 3rd, Calvert VS, Curiel-Lewandrowski C, Alberts DS, Wondrak GT, Dickinson SE.

Cancer Prev Res (Phila). 2018 May;11(5):265-278. doi: 10.1158/1940-6207.CAPR-17-0349. Epub 2018 Feb 1.

15.

Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis.

Ding KF, Petricoin EF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ.

Oncotarget. 2017 Dec 15;9(4):5044-5057. doi: 10.18632/oncotarget.23495. eCollection 2018 Jan 12.

16.

Phosphoproteomic analysis reveals Smad protein family activation following Rift Valley fever virus infection.

de la Fuente C, Pinkham C, Dabbagh D, Beitzel B, Garrison A, Palacios G, Hodge KA, Petricoin EF, Schmaljohn C, Campbell CE, Narayanan A, Kehn-Hall K.

PLoS One. 2018 Feb 6;13(2):e0191983. doi: 10.1371/journal.pone.0191983. eCollection 2018. Erratum in: PLoS One. 2018 Mar 15;13(3):e0194633.

17.

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.

Olshen A, Wolf D, Jones EF, Newitt D, van ‘t Veer LJ, Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF 3rd, Hylton N, Park CC.

J Med Imaging (Bellingham). 2018 Jan;5(1):011014. doi: 10.1117/1.JMI.5.1.011014. Epub 2017 Dec 23.

18.

Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity.

Paris L, Magni R, Zaidi F, Araujo R, Saini N, Harpole M, Coronel J, Kirwan DE, Steinberg H, Gilman RH, Petricoin EF 3rd, Nisini R, Luchini A, Liotta L.

Sci Transl Med. 2017 Dec 13;9(420). pii: eaal2807. doi: 10.1126/scitranslmed.aal2807.

19.

Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL.

Jayappa KD, Portell CA, Gordon VL, Capaldo BJ, Bekiranov S, Axelrod MJ, Brett LK, Wulfkuhle JD, Gallagher RI, Petricoin EF, Bender TP, Williams ME, Weber MJ.

Blood Adv. 2017 Jun 13;1(14):933-946. Erratum in: Blood Adv. 2017 Aug 17;1(19):1537.

20.

Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example.

Eke I, Makinde AY, Aryankalayil MJ, Sandfort V, Palayoor ST, Rath BH, Liotta L, Pierobon M, Petricoin EF, Brown MF, Stommel JM, Ahmed MM, Coleman CN.

Mol Cancer Ther. 2018 Feb;17(2):355-367. doi: 10.1158/1535-7163.MCT-17-0262. Epub 2017 Aug 11.

21.

Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations.

Rao G, Pierobon M, Kim IK, Hsu WH, Deng J, Moon YW, Petricoin EF, Zhang YW, Wang Y, Giaccone G.

Sci Rep. 2017 Aug 1;7(1):7066. doi: 10.1038/s41598-017-06128-9.

22.

Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.

Sereni MI, Baldelli E, Gambara G, Ravaggi A, Hodge KA, Alberts DS, Guillen-Rodriguez JM, Dong T, Memo M, Odicino F, Angioli R, Liotta LA, Pecorelli SL, Petricoin EF, Pierobon M.

Br J Cancer. 2017 Aug 8;117(4):494-502. doi: 10.1038/bjc.2017.195. Epub 2017 Jun 29.

23.

Protein network construction using reverse phase protein array data.

Varghese RS, Zuo Y, Zhao Y, Zhang YW, Jablonski SA, Pierobon M, Petricoin EF, Ressom HW, Weiner LM.

Methods. 2017 Jul 15;124:89-99. doi: 10.1016/j.ymeth.2017.06.017. Epub 2017 Jun 24.

24.

The Warburg Effect and Mass Spectrometry-based Proteomic Analysis.

Zhou W, Liotta LA, Petricoin EF.

Cancer Genomics Proteomics. 2017 Jul-Aug;14(4):211-218. Review.

25.

Targetable T-type Calcium Channels Drive Glioblastoma.

Zhang Y, Cruickshanks N, Yuan F, Wang B, Pahuski M, Wulfkuhle J, Gallagher I, Koeppel AF, Hatef S, Papanicolas C, Lee J, Bar EE, Schiff D, Turner SD, Petricoin EF, Gray LS, Abounader R.

Cancer Res. 2017 Jul 1;77(13):3479-3490. doi: 10.1158/0008-5472.CAN-16-2347. Epub 2017 May 16.

26.

Mass Spectrometry-Based Biomarker Discovery.

Zhou W, Petricoin EF 3rd, Longo C.

Methods Mol Biol. 2017;1606:297-311. doi: 10.1007/978-1-4939-6990-6_19.

PMID:
28502008
27.

Reverse Phase Protein Microarrays.

Baldelli E, Calvert V, Hodge A, VanMeter A, Petricoin EF 3rd, Pierobon M.

Methods Mol Biol. 2017;1606:149-169. doi: 10.1007/978-1-4939-6990-6_11.

PMID:
28502000
28.

Innovations in Clinical Trial Design in the Era of Molecular Profiling.

Wulfkuhle JD, Spira A, Edmiston KH, Petricoin EF 3rd.

Methods Mol Biol. 2017;1606:19-36. doi: 10.1007/978-1-4939-6990-6_2. Review.

PMID:
28501991
29.

Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.

Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle J, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK.

Mol Cancer Ther. 2017 Jul;16(7):1389-1400. doi: 10.1158/1535-7163.MCT-17-0111. Epub 2017 May 3.

30.

Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.

Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland-Jones B, Liotta LA, O'Shaughnessy JA, Carpten JD, Petricoin EF.

Clin Cancer Res. 2017 Aug 15;23(16):4919-4928. doi: 10.1158/1078-0432.CCR-16-2656. Epub 2017 Apr 26.

31.

Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine.

Parasido EM, Silvestri A, Canzonieri V, Belluco C, Diodoro MG, Milione M, Melotti F, De Maria R, Liotta L, Petricoin EF, Pierobon M.

Oncotarget. 2017 Jul 25;8(30):48534-48544. doi: 10.18632/oncotarget.14019.

32.

The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma.

Simbulan-Rosenthal CM, Dakshanamurthy S, Gaur A, Chen YS, Fang HB, Abdussamad M, Zhou H, Zapas J, Calvert V, Petricoin EF, Atkins MB, Byers SW, Rosenthal DS.

Oncotarget. 2017 Feb 21;8(8):12576-12595. doi: 10.18632/oncotarget.14990.

33.

Resatorvid-based Pharmacological Antagonism of Cutaneous TLR4 Blocks UV-induced NF-κB and AP-1 Signaling in Keratinocytes and Mouse Skin.

Janda J, Burkett NB, Blohm-Mangone K, Huang V, Curiel-Lewandrowski C, Alberts DS, Petricoin EF 3rd, Calvert VS, Einspahr J, Dong Z, Bode AM, Wondrak GT, Dickinson SE.

Photochem Photobiol. 2016 Nov;92(6):816-825. doi: 10.1111/php.12659. Epub 2016 Dec 8.

34.

Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis.

Ceglia I, Dueck AC, Masiello F, Martelli F, He W, Federici G, Petricoin EF 3rd, Zeuner A, Iancu-Rubin C, Weinberg R, Hoffman R, Mascarenhas J, Migliaccio AR.

Exp Hematol. 2016 Dec;44(12):1138-1155.e4. doi: 10.1016/j.exphem.2016.08.007. Epub 2016 Aug 31.

35.

D3D augmented reality imaging system: proof of concept in mammography.

Douglas DB, Petricoin EF, Liotta L, Wilson E.

Med Devices (Auckl). 2016 Aug 9;9:277-83. doi: 10.2147/MDER.S110756. eCollection 2016.

36.

The Obama Administration's Cancer Moonshot: A Call for Proteomics.

Conrads TP, Petricoin EF 3rd.

Clin Cancer Res. 2016 Sep 15;22(18):4556-8. doi: 10.1158/1078-0432.CCR-16-0688. Epub 2016 May 19.

37.

Erratum to: 'Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology'.

Bianconi F, Baldelli E, Ludovini V, Petricoin EF, Crinò L, Valigi P.

BMC Syst Biol. 2016 Mar 2;10:24. doi: 10.1186/s12918-016-0267-2. No abstract available.

38.

Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin.

Dickinson SE, Janda J, Criswell J, Blohm-Mangone K, Olson ER, Liu Z, Barber C, Petricoin EF 3rd, Calvert VS, Einspahr J, Dickinson JE, Stratton SP, Curiel-Lewandrowski C, Saboda K, Hu C, Bode AM, Dong Z, Alberts DS, Timothy Bowden G.

Cancer Prev Res (Phila). 2016 Mar;9(3):215-24. doi: 10.1158/1940-6207.CAPR-15-0419. Epub 2016 Jan 22.

39.

Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest.

Capello M, Ferri-Borgogno S, Riganti C, Chattaragada MS, Principe M, Roux C, Zhou W, Petricoin EF, Cappello P, Novelli F.

Oncotarget. 2016 Feb 2;7(5):5598-612. doi: 10.18632/oncotarget.6798.

40.

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, Samatar AA, Maitra A, Wennerberg K, Petricoin EF 3rd, Yin HH, Nelkin B, Cox AD, Yeh JJ, Der CJ.

Cancer Cell. 2016 Jan 11;29(1):75-89. doi: 10.1016/j.ccell.2015.11.011. Epub 2015 Dec 24.

41.

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.

Roller DG, Capaldo B, Bekiranov S, Mackey AJ, Conaway MR, Petricoin EF, Gioeli D, Weber MJ.

Oncotarget. 2016 Jan 19;7(3):2734-53. doi: 10.18632/oncotarget.6548.

42.

Application of Nanotrap technology for high sensitivity measurement of urinary outer surface protein A carboxyl-terminus domain in early stage Lyme borreliosis.

Magni R, Espina BH, Shah K, Lepene B, Mayuga C, Douglas TA, Espina V, Rucker S, Dunlap R, Petricoin EF, Kilavos MF, Poretz DM, Irwin GR, Shor SM, Liotta LA, Luchini A.

J Transl Med. 2015 Nov 4;13:346. doi: 10.1186/s12967-015-0701-z.

43.

Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology.

Bianconi F, Baldelli E, Ludovini V, Petricoin EF, Crinò L, Valigi P.

BMC Syst Biol. 2015 Oct 19;9:70. doi: 10.1186/s12918-015-0216-5. Erratum in: BMC Syst Biol. 2016;10:24. Luovini, Vienna [corrected to Ludovini, Vienna].

44.

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.

Baldelli E, Bellezza G, Haura EB, Crinó L, Cress WD, Deng J, Ludovini V, Sidoni A, Schabath MB, Puma F, Vannucci J, Siggillino A, Liotta LA, Petricoin EF 3rd, Pierobon M.

Oncotarget. 2015 Oct 20;6(32):32368-79. doi: 10.18632/oncotarget.5941.

45.

Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.

Capaldo BJ, Roller D, Axelrod MJ, Koeppel AF, Petricoin EF, Slingluff CL Jr, Weber MJ, Mackey AJ, Gioeli D, Bekiranov S.

PLoS One. 2015 Sep 25;10(9):e0138210. doi: 10.1371/journal.pone.0138210. eCollection 2015.

46.

Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.

LeBlanc FR, Liu X, Hengst J, Fox T, Calvert V, Petricoin EF 3rd, Yun J, Feith DJ, Loughran TP Jr.

Cancer Biol Ther. 2015;16(12):1830-40. doi: 10.1080/15384047.2015.1078949.

47.

Activation of the PI3K/Akt/mTOR and MAPK Signaling Pathways in Response to Acute Solar-Simulated Light Exposure of Human Skin.

Bermudez Y, Stratton SP, Curiel-Lewandrowski C, Warneke J, Hu C, Bowden GT, Dickinson SE, Dong Z, Bode AM, Saboda K, Brooks CA, Petricoin EF 3rd, Hurst CA, Alberts DS, Einspahr JG.

Cancer Prev Res (Phila). 2015 Aug;8(8):720-8. doi: 10.1158/1940-6207.CAPR-14-0407. Epub 2015 Jun 1.

48.

Host response during Yersinia pestis infection of human bronchial epithelial cells involves negative regulation of autophagy and suggests a modulation of survival-related and cellular growth pathways.

Alem F, Yao K, Lane D, Calvert V, Petricoin EF, Kramer L, Hale ML, Bavari S, Panchal RG, Hakami RM.

Front Microbiol. 2015 Feb 13;6:50. doi: 10.3389/fmicb.2015.00050. eCollection 2015.

49.

Multifactorial analysis of conditional reprogramming of human keratinocytes.

Ligaba SB, Khurana A, Graham G, Krawczyk E, Jablonski S, Petricoin EF, Glazer RI, Upadhyay G.

PLoS One. 2015 Feb 25;10(2):e0116755. doi: 10.1371/journal.pone.0116755. eCollection 2015.

50.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ.

Clin Cancer Res. 2015 Jul 1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24.

Supplemental Content

Loading ...
Support Center